Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747884 · ClinicalTrials.gov registry record
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
A clinical trial of Myotonic Dystrophy and Congenital Myotonic Dystrophy, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06747884: Recruiting study of Myotonic Dystrophy and Congenital Myotonic Dystrophy, sponsored by Virginia Commonwealth University.
NCT06747884 is a study of Myotonic Dystrophy and Congenital Myotonic Dystrophy that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 200 participants, below the 833-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06747884, a study of Myotonic Dystrophy and Congenital Myotonic Dystrophy, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
Primary Outcome
The participant will be timed walking or running along a 10-meter course. It is scored by recording the total time taken to ambulate 6 meters (m) is recorded to the nearest hundredth of a second. 6 m is then divided by the total time (in seconds) taken to ambulate and recorded in m/s.
Conditions Studied
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2030-06 |
What NCT06747884 shows while recruiting
NCT06747884 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 833-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT06747884 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06747884 about?
NCT06747884 is a clinical study titled "Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension". This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
What is the current status of trial NCT06747884?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-06-06. Estimated completion is 2030-06.
What conditions does trial NCT06747884 study?
This clinical trial studies the following conditions: Myotonic Dystrophy, Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy.
Who is sponsoring clinical trial NCT06747884?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747884 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06747884's enrollment target sits among peer trials
200 5th of 9 higher than 5 of 9 other Myotonic Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myotonic Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
-
Myotonic Dystrophy Family Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI